Table 1 Baseline demographics and clinical characteristics of the study population
Catumaxomab + FLOT (Arm A) N = 15 | FLOT (Arm B) N = 16 | |
|---|---|---|
Age, years | ||
Median (range, IQR) | 56 (25–77, 49–63) | 52 (38–73, 43–62) |
Sex, male | 7 (47%) | 10 (62%) |
ECOG performance status | ||
0 | 7 (50%) | 8 (50%) |
1 | 7 (50%) | 7 (44%) |
2 | – | 1 (6%) |
Primary site | ||
Stomach | 14 (93%) | 11 (69%) |
Oesophago-gastric junction | 1 (7%) | 5 (31%) |
TNM-Classification | ||
T3 | 9 (60%) | 10 (63%) |
T4 | 4 (27%) | 4 (25%) |
Tx | 2 (13%) | 2 (12%) |
N0 | 3 (20%) | 3 (19%) |
N+ | 10 (67%) | 11 (69%) |
Nx | 2 (13%) | 2 (12%) |
M1 (Peritoneal carcinomatosis) | 15 (100%) | 16 (100%) |
Gilly classification | ||
P1 | 1 (7%) | 1 (6%) |
P2 + P3 | 9 (60%) | 10 (63%) |
P4 | 5 (33%) | 5 (31%) |
Peritoneal Cancer Index (PCI) | ||
Median (range, IQR) | 8 (1–34, 5–17) | 12 (1–33, 3–19) |
